trending Market Intelligence /marketintelligence/en/news-insights/trending/_e41rsx07c46m1de90-q4g2 content esgSubNav
In This List

Report: Swiss specialty pharma Polyphor plans CHF 100M IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Report: Swiss specialty pharma Polyphor plans CHF 100M IPO

Switzerland-based Polyphor Ltd. is planning to file for an IPO in the second quarter of 2018, Reuters reported, citing anonymous sources.

The Swiss company is looking to raise more than CHF 100 million in the IPO to advance its pipeline. It could have a value of about CHF 500 million after it goes public, according to one of Reuters' sources.

Polyphor is working with UBS and Deutsche Bank for the transaction, Reuters reported.

Polyphor is a specialty pharmaceutical company focused on developing macrocycle drugs to address antibiotic resistance and severe respiratory diseases. Its lead drug candidate, Murepavadin, is being studied in a phase 3 study as a potential treatment for nosocomial pneumonia caused by the pseudomonas aeruginosa bacteria.